Support and Resistance Levels
Past performance
About Fabtech Technologies Ltd Fabtech Technologies Limited is a turnkey engineering solutions provider specializing in pharmaceutical capital expenditure projects. Originally incorporated as Globeroute Ventures Private Limited in 2018, the company underwent several transitions, including name changes and conversion to a public company, achieving its current status in July 2024. It offers end-to-end solutions spanning design, engineering, procurement, installation, and testing of pharmaceutical equipment, catering to diverse customers in the global pharmaceutical market.
Fabtech leverages extensive expertise in executing international turnkey projects. Significant milestones include completing installations of cleanroom doors for a state-owned organization in Bangladesh (2022), processing equipment for a pharmaceutical manufacturer in Algeria (2023), and manufacturing facilities in Saudi Arabia for oral solid dosage, liquid oral dosage, and disinfectants (2023). The export division of Fabtech Technologies International Private Limited was demerged into Fabtech in 2020, further solidifying the company’s operational capabilities and reinforcing the roles of its promoters: Aasif Ahsan Khan, Hemant Mohan Anavkar, Aarif Ahsan Khan, and Manisha Hemant Anavkar.
In 2024, Fabtech expanded its portfolio and geographic reach through strategic acquisitions. It acquired FT Institutions Private Limited and FABL International Technologies LLP to enhance capabilities in process solutions for oral solid dosage. The company also gained controlling stakes in TSA Process Equipments Private Limited, strengthening its foothold in process equipment manufacturing. Fabtech established subsidiaries in Sharjah, UAE, (Fabtech Technologies LLC and FTS Cleanrooms Systems LLC) to maintain operations in the Middle East. Additionally, FTS Cleanrooms Systems LLC acquired business undertakings from FTS Lifecare Technical Services LLC in May 2024.
Fabtech Technologies Limited is preparing for an IPO, offering 1,20,60,000 equity shares with a face value of Rs. 10/- each through fresh issuance, signaling growth and expansion potential for traders and investors interested in the pharmaceutical engineering sector.